SAGE Therapeutics (NASDAQ:SAGE) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($3.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.41) by ($0.07), Fidelity Earnings reports. SAGE Therapeutics had a negative return on equity of 59.37% and a negative net margin of 12,931.34%. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $2.52 million. During the same period in the prior year, the company posted ($2.63) EPS. The firm’s quarterly revenue was up 35600.0% compared to the same quarter last year.
Shares of SAGE traded up $3.43 during trading hours on Friday, reaching $144.22. The stock had a trading volume of 1,893 shares, compared to its average volume of 366,793. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a 52 week low of $79.88 and a 52 week high of $193.56. The firm has a 50-day moving average of $141.94 and a 200 day moving average of $163.62. The company has a market cap of $7.31 billion, a P/E ratio of -17.75 and a beta of 2.49.
Several research analysts have issued reports on SAGE shares. Canaccord Genuity reduced their price objective on SAGE Therapeutics from $220.00 to $218.00 and set a “buy” rating on the stock in a report on Wednesday. JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. ValuEngine cut shares of SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday. William Blair restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Finally, Oppenheimer lowered their price objective on shares of SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. SAGE Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $201.00.
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Recommended Story: What is Net Asset Value (NAV)?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.